文章：

子宫内膜癌研究新进展：分子分型整合入分期系统以提升预后准确性及其对种族差异的影响

Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities

原文发布日期：16 March 2024

DOI: 10.3390/cancers16061172

类型: Article

开放获取: 是

英文摘要：

Since the 2009 FIGO staging update, focused exclusively on the anatomic extent of disease, there have been several advances in the understanding of the pathologic and molecular features of endometrial cancer. In a significant departure from the 2009 FIGO staging system, the 2023 FIGO staging update integrates both histopathological and molecular classification. With the inclusion of non-anatomic pathologic parameters such as histology, tumor grade, lymphovascular space invasion, and molecular subtype, the 2023 FIGO staging update aims to create more clinically relevant substages that improve prognostic value and allows for more individualized treatment paradigms. This review will evaluate the clinical impact of the 2023 FIGO staging update, describe the stage shifts that lead to higher prognostic precision, and illustrate the current state of molecular analysis in clinical practice. Furthermore, this review will explore how incorporating factors such as molecular subtype into endometrial cancer staging can offer valuable insights into the racial disparities seen in morbidity and mortality.

摘要翻译： 

自2009年国际妇产科联盟（FIGO）分期系统仅关注疾病解剖范围以来，子宫内膜癌的病理学和分子特征研究已取得多项进展。与2009年FIGO分期系统相比，2023年FIGO分期更新实现了重大突破，将组织病理学与分子分型整合入分期体系。通过纳入组织学类型、肿瘤分级、淋巴血管间隙浸润及分子亚型等非解剖病理参数，新版分期系统旨在建立更具临床相关性的亚分期，以提升预后评估价值，并为个体化治疗模式的构建提供依据。本文综述将评估2023年FIGO分期更新的临床意义，阐述提升预后精准度的分期迁移机制，并探讨分子分析在临床实践中的应用现状。此外，本文还将深入分析将分子亚型等因素纳入子宫内膜癌分期体系，如何为解析该疾病发病率与死亡率的种族差异提供新的视角。

原文链接：

Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities